Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”

Article information

Clin Mol Hepatol. 2025;31(2):e186-e188
Publication date (electronic) : 2025 January 24
doi : https://doi.org/10.3350/cmh.2025.0079
Hepatobiliary Surgery, Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China
Corresponding author : Jin-Hong Chen Hepatobiliary Surgery, Department of General Surgery, Huashan Hospital, Fudan University, 12 Urumqi Road, Shanghai 200040, China Tel: +86-021-5288-9640, Fax: +86-021-5288-9640, E-mail: jinhongch@hotmail.com
Jing Lin Hepatobiliary Surgery, Department of General Surgery, Huashan Hospital, Fudan University, 12 Urumqi Road, Shanghai 200040, China Tel: +86-021-5288-9640, Fax: +86-021-5288-9640, E-mail: linjingfdu@163.com
*These authors contributed equally to this work.
Editor: Han Ah Lee, Chung-Ang University College of Medicine, Korea
Received 2025 January 21; Accepted 2025 January 23.

Dear Editor,

We are grateful to Drs. Yoon-su Ha, Won Kim, and Seung-Jin Kim for their valuable feedback regarding our findings [1]. As one of the most prevalent chronic liver diseases, metabolic dysfunction-associated steatohepatitis (MASH) is associated with the onset of cholesterol gallstone (CGS) formation [2,3]. Golgi membrane protein 1 (GOLM1) increases ATP-binding cassette subfamily G member 5 (ABCG5)-mediated cholesterol efflux in an osteopontin (OPN)-dependent manner, promoting MASH-related CGS formation [2]. Moreover, interleukin-1β (IL-1β), a crucial inflammatory factor in MASH, increases GOLM1 expression and promotes its nuclear translocation [2]. As noted in the comments, multifaceted challenges remain, including sex-specific factors, the construction of gene-edited mice, and the application of disease models, which must be addressed to increase the translational potential of the research.

Sex is one of the most important factors affecting metabolic diseases, including MASH and gallstones [4,5]. Owing to the effects of hormones, particularly estrogen, females are more susceptible to cholesterol gallstones than males are [4,6]. Moreover, a recent study showed that estrogen protects against MASH [7]. The liver, a vital metabolic organ, is crucial for maintaining cholesterol homeostasis, with cholesterol being a key toxic molecule in MASH progression [8]. Estrogen potentially inhibits the progression of MASH by increasing hepatic exocytosis of cholesterol, which could lead to biliary cholesterol supersaturation and CGS formation. Cholesterol can be converted into steroid hormones such as estradiol [9]. Our previous study revealed that GOLM1 expression can be regulated by cholesterol [10]. Therefore, sex-related factors such as estrogen may contribute to the formation of MASH-associated CGSs by regulating GOLM1 expression. Our study focused on the role of GOLM1 in MASH-related CGS formation [2]. To ensure the reliability of the study, we controlled for sex as a confounder to exclude potential interference. Although this design avoided interference from the above factors in the study results, it prevented us from assessing the effects of sex-related factors, especially estrogen, on MASH-related gallstone formation. Further clinical and fundamental research is needed to clarify the impact of sex on MASH-related CGSs.

Global knockout is a well-established gene editing technique that accurately reflects gene function and prevents residual expression of the knocked out gene. However, global knockouts may induce compensatory effects and lack spatial and temporal specificity. GOLM1 is a Golgi type II transmembrane protein that is found mainly in the liver and that participates in protein transport and modification [2]. It is normally expressed at low levels in hepatocytes but is highly expressed in MASH livers [2]. Moreover, high GOLM1 expression is associated with pathological features of MASH, such as liver inflammation and fibrosis, suggesting that GOLM1 plays a specific role in MASH [2]. Considering the liver specificity of GOLM1 expression, global gene knockout could fulfill these research needs to some extent. Tissue-specific knockout mice will help explore the role of GOLM1 in specific tissues in MASH-related CGS formation while minimizing compensatory effects from other tissues. Although GOLM1 is specifically expressed in the liver, secreted GOLM1 may originate from other tissues, so efforts should focus on excluding its influence. Adipose tissue is one of the major components of the human body and plays an important role in regulating metabolism and inflammation [11]. In addition to regulating cholesterol metabolism, GOLM1 is involved in the inflammatory response [12]. Hence, adipose tissue may regulate GOLM expression, thus impacting MASH-associated CGS formation. The presence of GOLM1 in adipose tissue and the role of adipose tissue-derived GOLM1 in MASH-related CGSs are promising directions and need to be further explored.

A high-fat, high-carbohydrate diet predominates in Western society, and feeding animals this type of diet is the traditional approach used to construct animal models of metabolic dysfunction-associated fatty liver disease (MAFLD) and MASH [1,13,14]. Our study demonstrated that all the mice fed a high-fat diet (HFD) developed MASH, which was accompanied by liver inflammation and ballooning [2]. However, as noted in the comments, MASH is a complex liver disease, and findings are best validated using multiple models. Common dietary methods for modeling MASH include fatty acid diets, choline-deficient L-amino-defined diets (CDAA), methionine choline-deficient diets (MCD), and high-fat, high-cholesterol diets (HFHC) [13]. These diets can be used to establish both acute and chronic MASH models, providing more comprehensive data to support research. Importantly, animal models cannot fully replicate human MASH, and additional clinical data are required to bridge this gap [15].

Notes

Authors’ contribution

Yi-Tong Li, Wei-Qing Shao, and Zhen-Mei Chen designed and wrote the manuscript; Jin-Hong Chen and Jing Lin supervised the manuscript.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (Grant No. 82272836, 82470667) and Shanghai Excellent Academic Leaders Program (Grant No. 22XD1400300).

Conflicts of Interest

The authors declare no competing interests.

Abbreviations

ABCG5/8

ATP-binding cassette subfamily G member 5/8

CDAA

choline-deficient L-amino-defined diets

CGS

cholesterol gallstone

GOLM1

golgi membrane protein 1

HFD

high-fat diet

HFHC

high-fat

IL-1β

interleukin-1β

MAFLD

metabolic dysfunction-associated fatty liver disease

MASH

metabolic dysfunction-associated steatohepatitis

MCD

methionine choline-deficient diets

OPN

osteopontin

References

1. Ha YS, Kim W, Kim SJ. Unraveling the role of GOLM1-OPNABCG5 axis in MASH: Editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”. Clin Mol Hepatol 2025;31:628–630.
2. Li YT, Shao WQ, Chen ZM, Ma XC, Yi CH, Tao BR, et al. GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in metabolic dysfunction-associated steatohepatitis livers. Clin Mol Hepatol 2025;31:409–425.
3. Yoo JJ, Kim W, Kim MY, Jun DW, Kim SG, Yeon JE, et al. Recent research trends and updates on nonalcoholic fatty liver disease. Clin Mol Hepatol 2019;25:1–11.
4. Lammert F, Gurusamy K, Ko CW, Miquel JF, Méndez-Sánchez N, Portincasa P, et al. Gallstones. Nat Rev Dis Primers 2016;2:16024.
5. Balakrishnan M, Patel P, Dunn-Valadez S, Dao C, Khan V, Ali H, et al. Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2021;19:61–71.e15.
6. Everson GT, McKinley C, Kern F Jr. Mechanisms of gallstone formation in women. Effects of exogenous estrogen (premarin) and dietary cholesterol on hepatic lipid metabolism. J Clin Invest 1991;87:237–246.
7. Yang M, Liu Q, Huang T, Tan W, Qu L, Chen T, et al. Dysfunction of estrogen-related receptor alpha-dependent hepatic VLDL secretion contributes to sex disparity in NAFLD/NASH development. Theranostics 2020;10:10874–10891.
8. Musso G, Gambino R, Cassader M. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog Lipid Res 2013;52:175–191.
9. Yaspan BL, Breyer JP, Cai Q, Dai Q, Elmore JB, Amundson I, et al. Haplotype analysis of CYP11A1 identifies promoter variants associated with breast cancer risk. Cancer Res 2007;67:5673–5682.
10. Shao WQ, Zhu WW, Luo MJ, Fan MH, Li Q, Wang SH, et al. Cholesterol suppresses GOLM1-dependent selective autophagy of RTKs in hepatocellular carcinoma. Cell Rep 2022;39:110712.
11. Lee KC, Wu PS, Lin HC. Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis. Clin Mol Hepatol 2023;29:77–98.
12. Pu Y, Song Y, Zhang M, Long C, Li J, Wang Y, et al. GOLM1 restricts colitis and colon tumorigenesis by ensuring Notch signaling equilibrium in intestinal homeostasis. Signal Transduct Target Ther 2021;6:148.
13. Gallage S, Avila JEB, Ramadori P, Focaccia E, Rahbari M, Ali A, et al. A researcher’s guide to preclinical mouse NASH models. Nat Metab 2022;4:1632–1649.
14. Semmler G, Datz C, Trauner M. Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease. Clin Mol Hepatol 2023;29(Suppl):S244–S260.
15. Javor ED, Ghany MG, Cochran EK, Oral EA, DePaoli AM, Premkumar A, et al. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 2005;41:753–760.

Article information Continued